Methods of making pancreatic islet cells

• US 6,815,203 B1
• Filed: 06/23/2000
• Issued: 11/09/2004
• Est. Priority Date: 06/23/1999
• Status: Expired due to Fees

• Current Assignee: Joslin Diabetes Center Inc.
• Original Assignee: Joslin Diabetes Center Inc.
• Inventors: Taneja, Monica, Bonner-Weir, Susan
• Primary Examiner(s): Afremova, Vera
• Application Number:
  US09/602,508
• Time in Patent Office: 1,600 Days
• Field of Search: 435/377, 435/375, 435/384, 435/366, 435/370, 435/325
• US Class Current: 435/377
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 2506/22 from pancreatic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The invention features methods of promoting dedifferentiation of pancreatic cells, methods of obtaining pancreatic islet cells from the dedifferentiated pancreatic cells, and methods of treating a subject having a disorder characterized by insufficient pancreatic islet function by administering pancreatic islet cells obtained by these methods.

Claims

1. A method of obtaining pancreatic islet cells, the method comprising:

providing differentiated pancreatic duct or exocrine cells substantially free of islet cells,

allowing said differentiated duct or exocrine cells to proliferate to form a population of dedifferentiated pancreatic cells;

adding a component of extracellular matrix (ECM) to the population of dedifferentiated pancreatic cells; and

growing the cells in the presence of the component of ECM for a time sufficient for the dedifferentiated cells to express insulin, thereby obtaining pancreatic islet cells.

2. The method of claim 1, wherein the population of dedifferentiated pancreatic cells has been cultured until at least about 70% confluency before adding a component of the extracellular matrix.

3. The method of claim 1, wherein the dedifferentiated pancreatic cells express cytokeratin.

4. The method of claim 1, wherein the component of extracellular matrix is laminin.

5. The method of claim 1, wherein the component of extracellular matrix is a basement membrane derived substance.

6. The method of claim 5, wherein the basement membrane is laid down by an Engelbreth-Holm-Swarm tumor cell.

7. The method of claim 1, wherein the component of extracellular matrix is added by overlaying the population of dedifferentiated cells.

8. The method of claim 1, wherein at least a portion of the pancreatic islet cells form cultivated islet buds.

9. The method of claim 8, wherein the cultivated islet buds comprise hormone positive islet cells.

10. The method of claim 8, wherein the cultivated islet cells express increased levels of insulin expression as compared to the dedifferentiated cells.

11. The method of claim 1, wherein the pancreatic islet cells have the ability to secrete insulin in response to glucose.

27. The method of claim 1, or 12, wherein the component of extracellular matrix is collagen.

28. The method of claim 1, or 12, wherein the component of extracellular matrix is entactin.

29. The method of claim 1, or 12, wherein the component of extracellular matrix is heparin sulfate proteoglycan.

30. The method of claim 1, or 12, wherein the component of extracellular matrix is nidogen.

31. The method of claim 1, wherein the proliferation is characterized by expression of IPF-1.

32. The method of claim 1, wherein the proliferation is characterized by expression of PDX-1.

33. The method of claim 1, wherein the proliferation is characterized by expression of Pref-1.

12. A method of obtaining pancreatic islet cells, the method comprising:

(a) obtaining a population of adult or differentiated pancreatic cells substantially free of islet cells,

(b) allowing the adult or differentiated pancreatic cells to proliferate to form a population of dedifferentiated pancreatic cells;

(c) adding a component of extracellular matrix (ECM) to the population of dedifferentiated pancreatic cells; and

(d) growing the cells in the presence of the component of ECM for a time sufficient for the dedifferentiated cells to express insulin, thereby obtaining pancreatic islet cells.

13. The method of claim 12, wherein the population of adult or differentiated pancreatic cells substantially free of islet cells is obtained from cells remaining after islet isolation from a pancreatic tissue.

14. The method of claim 12, wherein the population of adult or differentiated pancreatic cells substantially free of islet cells is selected based on their ability to adhere to a container.

15. The method of claim 12, wherein the dedifferentiated pancreatic cells express cytokeratin.

16. The method of claim 12, wherein the component of extracellular matrix is laminin.

17. The method of claim 12, wherein the component of extracellular matrix is added by overlaying the population of dedifferentiated cells.

18. The method of claim 12, wherein at least a portion of the pancreatic islet cells form cultivated islet buds.

19. The method of claim 18, wherein the cultivated islet buds comprises hormone positive islet cells.

20. The method of claim 12, wherein the pancreatic islet cells have the ability to secrete insulin in response to glucose.

21. The method of claim 12, wherein in step (b) an agent that promotes expansion is added to the adult or differentiated pancreatic cells.

22. The method of claim 21, wherein the agent is a growth factor or a combination of growth factors.

23. The method of claim 22, wherein the growth factor is selected from the group consisting of:

keratinocyte growth factor, epidermal growth factor, transforming growth factor-α

, hepatocyte growth factor, and combinations thereof.

24. The method of claim 23, wherein the growth factor is keratinocyte growth factor.

25. The method of claim 12, wherein in step (b) the adult or differentiated pancreatic cells are placed on a substrate in a glucose-containing media.

26. The method of claim 12, wherein the population of adult or differentiated pancreatic cells is cultured until at least about 70% confluency before adding the component of extracellular matrix.

34. The method of claim 12, wherein the proliferation is characterized by expression of IPF-1.

35. The method of claim 12, wherein the proliferation is characterized by expression of PDX-1.

36. The method of claim 12, wherein the proliferation is characterized by expression of Pref-1.